Home
AARTIDRUGS.NS

Aarti Drugs Limited

NSEHealthcare
₹386.60
+0.56%+₹2.15 today
₹0.00₹0.00
Ask Warren
Open
₹0.00
Prev close
₹384.45
Day range
₹0 – ₹0
52W range
₹318.95 – ₹564.05
Volume
1.9L
Avg vol (20D)
1.6L
Mkt cap
₹3,528.5Cr
P/E TTM
18.1×

Trade Aarti Drugs Limited with Artha

Sign in to place orders, set alerts, and sync your watchlist.

Sign in to trade

Company Metrics

Revenue (ttm)₹2565.31 Cr
Net Income (ttm)₹0.00
Shares Out9.13 Cr
EPS (ttm)
Forward PE
Dividend
Ex-Dividend DateInvalid Date

Trading Metrics

Beta0.35

About AARTIDRUGS.NS

Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, norfloxacin, ofloxacin, metronidazole, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzene sulphonyl chloride, benzene sulphonic acid, methyl benzenesulfonate, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfonyl chloride, formamide, calcium fluoride, potasium formate, benzenesulfonamide, ethyl p- toluenesulfonate, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, para chlorobenznesulfonamide, para toluenesulfonyl hydrazide, para toluenesulfonamide, and sodium benzenesulfonate. In addition, it offers pharma intermediate products, which includes Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide, Raloxifene, Tinidazole, and Zolpidem. Further, the company develops drugs for antifungal, cardiovascular, and antidiabetic therapeutic areas, as well as non-steroidal anti-inflammatory drugs. The company was incorporated in 1984 and is headquartered in Mumbai, India.

IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
Employees0
Stock ExchangeNSE
Ticker SymbolAARTIDRUGS.NS
AARTIDRUGS.NS · NSE
Financial Performance

In 2026, Aarti Drugs Limited's revenue was ₹2565.31 Cr, an increase of +6.40% compared to the previous year. Earnings were ₹0.00, an decrease of +12.00%.

Revenue (2026)
₹2565.31 Cr
+6.40% YoY
Earnings (2026)
₹0.00
-12.00% YoY
Year-over-Year Growth
Revenue
+6.40%
Earnings
-12.00%

News

Save watchlists across devicesSet price alerts that buzz your phoneConnect Zerodha for one-tap trades
Create free account

We use analytics cookies to understand how you use Artha and improve your experience. No data is sold to third parties.